Senate Bill No. 169, introduced by Senator Talbot, aims to enhance the regulations surrounding biomarker testing in Louisiana. The bill amends existing law to clarify the criteria for establishing clinical utility, stating that a biomarker test is considered clinically useful if it meets any of the specified criteria. Additionally, it ensures that health coverage plans provide biomarker testing without disruptions in care, such as the need for multiple biopsies, and mandates that coverage cannot be denied based on laboratory classifications or credentialing standards that are not directly related to the test's performance.

Furthermore, the bill resolves any conflicts between the provisions related to biomarker testing and those concerning genetic testing for cancer screening. The new provisions will take effect upon the governor's signature or after the designated time for gubernatorial action if not signed. The amendments and new sections aim to provide clearer guidelines and protections for patients requiring biomarker testing, ensuring they receive necessary care without unnecessary barriers.

Statutes affected:
SB169 Original: 22:5(D)